4//SEC Filing
TAKEDA PHARMACEUTICAL CO LTD 4
Accession 0001395064-25-000172
$TAKCIK 0001636651other
Filed
Dec 8, 7:00 PM ET
Accepted
Dec 9, 9:19 PM ET
Size
10.2 KB
Accession
0001395064-25-000172
Insider Transaction Report
Form 4
TAKEDA PHARMACEUTICAL CO LTD
10% Owner
Transactions
- Conversion
Common Stock
2025-12-08+1,250,000→ 7,000,000 total(indirect: See Explanation of Responses) - Conversion
Series A Convertible Preferred Stock
2025-12-08−1,250→ 0 total(indirect: See Explanation of Responses)Exercise: $0.00→ Common Stock (1,250 underlying)
Holdings
- 1,781,996
Common Stock
Takeda Pharmaceuticals U.S.A., Inc.
10% Owner
Transactions
- Conversion
Common Stock
2025-12-08+1,250,000→ 7,000,000 total(indirect: See Explanation of Responses) - Conversion
Series A Convertible Preferred Stock
2025-12-08−1,250→ 0 total(indirect: See Explanation of Responses)Exercise: $0.00→ Common Stock (1,250 underlying)
Holdings
- 1,781,996
Common Stock
Footnotes (3)
- [F1]Each share of Series A convertible preferred stock (the "Preferred Stock") of Ovid Therapeutics Inc. ("Ovid") was convertible into 1,000 shares of Ovid's common stock at any time at the election of TPUSA. On December 8, 2025, TPUSA elected to convert all 1,250 shares of Preferred Stock held by TPUSA.
- [F2]The reportable securities are directly held by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"). TPUSA is a direct subsidiary of Takeda Pharmaceuticals International AG. Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As such, Takeda may be deemed to have indirect beneficial ownership of the securities held by TPUSA.
- [F3]The Preferred Stock had no expiration date.
Documents
Issuer
Ovid Therapeutics Inc.
CIK 0001636651
Entity typeother
Related Parties
1- filerCIK 0001395064
Filing Metadata
- Form type
- 4
- Filed
- Dec 8, 7:00 PM ET
- Accepted
- Dec 9, 9:19 PM ET
- Size
- 10.2 KB